Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.
This article is for informational purposes only and does not constitute medical advice. These statements have not been evaluated by the Food and Drug Administration. Dietary supplements discussed in this content are not intended to diagnose, treat, cure, or prevent any disease. The drug interaction information presented here is for educational context and should not substitute for a medication review with your prescribing physician or pharmacist, who have access to your complete medication list and health history. UTCardiothoracicSurgery.com does not formulate or sell any product reviewed on this domain.
Medical Disclaimer: Drug interactions described in this article are based on published pharmacokinetic and pharmacodynamic research and clinical case literature. Individual responses to supplement-drug combinations vary. Always consult your cardiologist, prescribing physician, or pharmacist before adding any supplement to an existing medication regimen.
By UTCardiothoracicSurgery.com Editorial Team | Last reviewed: May 15, 2026
Quick Answer: Memopryl is not safe to combine with warfarin, simvastatin, atorvastatin, digoxin, or prescription cholinesterase inhibitors without a physician review. St. John's Wort in the formula reduces the effectiveness of those drugs through CYP enzyme induction; Huperzine-A adds direct cholinergic burden on top of any prescription Alzheimer's medications. A 2003 pharmacokinetic study found St. John's Wort reduced simvastatin blood concentration by 57%. For patients on those medications, that's not a theoretical risk — it's a documented drug exposure change. Memopezil carries lower but non-zero interaction risk via Panax Ginseng and calcium channel blockers.
Who This Safety Briefing Is For
Adults managing cardiovascular conditions — hypertension, heart failure, atrial fibrillation, coronary artery disease, post-MI, valve conditions — frequently research memory and cognitive supplements. This is not a coincidence: cardiovascular conditions and their treatments can affect cerebral blood flow, cognitive performance, and quality of life in ways that create legitimate reasons to explore cognitive support options.
The problem is that most nootropic supplement reviews are written for healthy adults with no medication considerations. The cardiovascular lens this platform applies changes the interaction picture meaningfully. This safety guide addresses both Memopezil and Memopryl specifically for the reader profile most likely to encounter them on this domain: adults managing one or more cardiovascular conditions on prescription medications.
St. John's Wort (Memopryl): The Highest-Priority Interaction
St. John's Wort (Hypericum perforatum) is the ingredient in Memopryl with the most extensively documented drug interaction profile. Its active compounds hypericin and hyperforin are potent inducers of CYP3A4, CYP2C9, and P-glycoprotein — three of the most important drug metabolism and transport pathways in the body. Induction of these pathways accelerates the metabolism of drugs that are CYP3A4 and CYP2C9 substrates, reducing their plasma concentrations and potentially compromising therapeutic effectiveness.
Cardiovascular medications directly affected:
Warfarin: A CYP2C9 substrate. St. John's Wort induces warfarin metabolism, reducing its anticoagulant effect. Multiple clinical studies have documented INR reductions in anticoagulated patients who added St. John's Wort. A 2000 study in the Lancet documented significant INR reductions in seven stable warfarin patients after two weeks of St. John's Wort use. For patients on warfarin therapy, this is a high-priority interaction — the consequence of reduced anticoagulation is increased clot risk.
Digoxin: A P-glycoprotein substrate. St. John's Wort induces P-glycoprotein, reducing digoxin absorption and increasing its renal elimination. A 1999 study documented digoxin plasma concentration reductions of 18-33% in patients who added St. John's Wort. For patients taking digoxin for heart failure or atrial fibrillation rate control, this interaction may compromise therapeutic effect.
Statins (simvastatin, atorvastatin): CYP3A4 substrates. St. John's Wort induction of CYP3A4 increases statin metabolism, reducing plasma concentrations. A 2003 pharmacokinetic study documented a 57% reduction in simvastatin AUC with concurrent St. John's Wort. For patients on statin therapy for cardiovascular risk management, this is a relevant interaction.
Calcium channel blockers (amlodipine, nifedipine, felodipine): CYP3A4 substrates. The same induction mechanism applies, potentially reducing calcium channel blocker effectiveness in blood pressure or angina management.
Huperzine-A (Memopryl): Cholinesterase Inhibitor Duplication
Huperzine-A is a reversible acetylcholinesterase inhibitor. The mechanism is parallel to prescription cholinesterase inhibitors used for Alzheimer's disease and vascular dementia: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). Taking Huperzine-A alongside any of these medications creates a cumulative cholinergic effect.
Cholinergic excess symptoms include: nausea, vomiting, diarrhea, increased salivation, sweating, bradycardia (slowed heart rate), and muscle weakness. In cardiac patients, bradycardia from cholinergic excess is a meaningful clinical concern, particularly for adults already on beta-blockers or other rate-controlling medications. The combination of a cholinesterase inhibitor and Huperzine-A in a patient also on rate-controlling cardiac medications creates a compounded bradycardia risk.
This isn't a theoretical concern. The mechanism is direct: one drug prevents acetylcholine breakdown, and so does the supplement. Any adult taking a prescription cholinesterase inhibitor for any indication needs to discuss Memopryl with their prescriber before use.
Ginkgo Biloba (Memopryl): Antiplatelet and Anticoagulant Interactions
Ginkgo Biloba inhibits platelet-activating factor (PAF) and has antiplatelet activity through ginkgolide B. This is additive with antiplatelet medications (aspirin, clopidogrel, ticagrelor) and may potentiate the effects of anticoagulants. Case reports exist of increased bleeding risk in patients taking Ginkgo alongside anticoagulants.
For adults on anticoagulation therapy — warfarin, apixaban, rivaroxaban, dabigatran — or on dual antiplatelet therapy after coronary stenting or MI, Ginkgo Biloba introduces a relevant interaction pathway that requires review before use. Memopryl contains Ginkgo Biloba at an undisclosed dosage.
Panax Ginseng (Memopezil): Calcium Channel Blocker and Anticoagulant Interactions
Panax Ginseng has documented pharmacokinetic interactions with nifedipine and other calcium channel blockers. A published pharmacokinetic study found that Panax Ginseng inhibited CYP3A4-mediated metabolism of nifedipine, potentially increasing plasma nifedipine concentrations. For patients on nifedipine for angina or hypertension, this interaction could affect blood pressure control.
Ginseng's effects on coagulation are variable, with some studies suggesting mild antiplatelet activity. Adults on anticoagulants should include Panax Ginseng in their drug interaction review with their pharmacist. Memopezil contains 90mg of Panax Ginseng Extract.
Condition-Specific Considerations
Atrial fibrillation: Adults with AFib are commonly on anticoagulation. Both Ginkgo Biloba (Memopryl) and Panax Ginseng (Memopezil) have antiplatelet properties relevant in this context. St. John's Wort (Memopryl) as a P-glycoprotein inducer affects some DOAC medications. Review with the anticoagulation management team is required before adding either supplement.
Heart failure: Digoxin is sometimes used in heart failure management. St. John's Wort's interaction with digoxin is well-documented and potentially clinically significant. Adults on digoxin should not take Memopryl without explicit digoxin level monitoring and physician review.
Post-MI or post-stenting on antiplatelet therapy: Ginkgo Biloba in Memopryl adds antiplatelet activity to a regimen already using aspirin or clopidogrel. Whether this creates meaningful excess bleeding risk depends on individual factors, but the appropriate setting to answer that question is a conversation with the prescribing cardiologist, not a self-management call.
General Safety Profile for Healthy Adults
For generally healthy adults not on cardiac medications, the ingredient safety profiles for both Memopezil and Memopryl are generally acceptable at standard doses. Memopezil's five-ingredient formula has a relatively clean interaction profile. Memopryl's formula carries St. John's Wort and Huperzine-A, which require a medication review for anyone on relevant co-medications.
Neither product is appropriate for pregnant or nursing individuals. Both products' labels caution against use in individuals under 18 or with known medical conditions without physician consultation. Both products carry the standard DSHEA disclaimer: not evaluated by the FDA, not intended to diagnose, treat, cure, or prevent any disease.
The cardiac drug interaction framework applied in this analysis is consistent with the methodology used across supplement evaluations on this domain. For the broader drug interaction framework covering PDE5 inhibitors and cardiovascular medications, see the cardiovascular drug interaction guide on this domain.
When to Consult a Physician Before Starting Either Product
Consult your physician or pharmacist before starting Memopryl if you take: warfarin or any anticoagulant; digoxin; any statin (simvastatin, atorvastatin, lovastatin); any calcium channel blocker; any antidepressant (particularly SSRIs or MAOIs — St. John's Wort + SSRI creates serotonin syndrome risk); any prescription cholinesterase inhibitor; cyclosporine or tacrolimus.
Consult your physician or pharmacist before starting Memopezil if you take: warfarin or other anticoagulants; calcium channel blockers (particularly nifedipine); antiplatelet medications.
When in doubt, the most efficient path is to bring the Supplement Facts label to your pharmacist. Pharmacists are trained in drug interaction assessment and can run a formal interaction check against your medication list in minutes. This applies to any supplement addition, not just these two products.
Frequently Asked Questions
Can you take nootropic supplements if you take warfarin?
Memopryl contains St. John's Wort (CYP2C9 inducer, reduces warfarin effect) and Ginkgo Biloba (antiplatelet, may potentiate warfarin). These interactions are documented in clinical literature. Memopezil contains Panax Ginseng, with less consistent but documented coagulation interactions. Both products require pharmacist review and likely INR monitoring before use in warfarin patients.
Is it safe to take memory supplements with blood pressure medications?
It depends on which blood pressure medications. Panax Ginseng (Memopezil) has documented interactions with nifedipine. St. John's Wort (Memopryl) reduces plasma concentrations of several calcium channel blockers via CYP3A4 induction. A pharmacist drug interaction review with your specific medication list is the appropriate evaluation step.
Can Memopryl be taken with cholesterol medications?
St. John's Wort in Memopryl induces CYP3A4, which metabolizes simvastatin and atorvastatin. A 2003 study documented a 57% reduction in simvastatin plasma concentration. Patients on statin therapy should discuss this with their cardiologist before starting Memopryl.
Are nootropic supplements safe for adults with atrial fibrillation?
Adults with AFib are typically on anticoagulation. Both Ginkgo Biloba (Memopryl) and Panax Ginseng (Memopezil) have antiplatelet activity relevant in this context. St. John's Wort affects P-glycoprotein, which transports some DOACs. The anticoagulation management team should review any supplement addition for AFib patients.
For the full formula comparison, see Memopezil vs Memopryl: Formula Transparency Report 2026. For the ingredient research deep-dive, see Nootropic Ingredient Research 2026. For the mechanism education article, see How Memory Consolidation Works: A 2026 Research Overview. For the four-product comparison, see Memory Supplements Compared 2026.
These statements have not been evaluated by the Food and Drug Administration. This content is for informational and educational purposes only and does not constitute medical or pharmacological advice. Individual drug interaction responses vary based on health status, specific medications, dosages, and other factors. Drug interaction information presented here is based on published research and is not a substitute for a review of your specific medication regimen with your prescribing physician or pharmacist. Consult a licensed healthcare provider before starting any supplement.